Aspirin increases nitric oxide formation in chronic stable coronary disease.

ABSTRACT:

Introduction

There are no published randomized data on secondary prevention in humans about whether aspirin affects nitric oxide (NO) formation. In patients with chronic stable coronary disease, we tested whether aspirin at clinically relevant doses increases NO formation.

Materials and methods

In a randomized, double-blind trial, 37 patients from 2 cardiology office practices were assigned to daily doses of 81, 162.5, 325, 650, or 1300 aspirin for 12 weeks. Primary prespecified outcome measures were changes in heme oxygenase (HO-1), a downstream target of NO formation, and asymmetrical dimethyl arginine (ADMA), a competitive inhibitor of NO synthase.

Results

There were no significant differences for HO-1 or ADMA between any of the clinically relevant doses of aspirin

SUBMITTER: Hetzel S 

PROVIDER: S-EPMC4014131 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature